NOVO B Novo Nordisk A/S Class B

Trading in Novo Nordisk shares by board members, executives and associated persons on 11 May 2020

Trading in Novo Nordisk shares by board members, executives and associated persons on 11 May 2020

Bagsværd, Denmark, 12 May 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.



Further information

Media:  
Mette Kruse Danielsen
Ken Inchausti (US)
   
Investors:  
Daniel Muusmann Bohsen
Valdemar Borum Svarrer
Ann Søndermølle Rendbæk
Mark Joseph Root
Kristoffer Due Berg US)

Company announcement No 33 / 2020

Attachment

EN
12/05/2020

Underlying

NOVO BNovo Nordisk A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 55,000 shares at 902.625DKK and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

NOVO B NOVO NORDISK A/S CLASS B
2h / 1m 2h / 1m 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK1100.00) - Small guidance raise

Q1 LCY figures beat consensus due to US rebate adjustments related to 2023 adding c5%-points to LCY growth and low SG&A cost boosting EBIT growth in Q1. Wegovy sales were below consensus but above our forecast, and we have therefore adjusted our rebate assumptions for 2024. The 2024 guidance was raised to LCY sales growth of 19–27% (18–26%) and LCY operating profit growth of 22–30% (21–29%). We reiterate our BUY and DKK1,100 target price.

NOVO B NOVO NORDISK A/S CLASS B
05/02/24 May 2, 2024 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK1100.00) - Company consensus added

We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.

NOVO B NOVO NORDISK A/S CLASS B
04/26/24 April 26, 2024 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK1100.00) - Ozempic to drive raised guidance

We are slightly below consensus on Q1 LCY sales growth (we forecast 19.4%, consensus 20.1%) and LCY operating profit growth (we forecast 16.8%, consensus 17.3%), due to lower expected Wegovy sales. However, we believe the trend in Ozempic US prescriptions will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.

NOVO B NOVO NORDISK A/S CLASS B
04/11/24 April 11, 2024 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK1100.00) - Raising the bar with amycretin

At its CMD, the company maintained its strategic aspirations for 2025. It also expects increasing operating profit margins in the coming years. A key focus was the phase I trial results for amycretin in obesity, showing 13.1% weight loss (no signs of plateau). While not confirmed, we still expect it to go directly to phase III development. We reiterate our BUY and have increased our target price to DKK1,100 (1,000) on higher pipeline valuation.

NOVO B NOVO NORDISK A/S CLASS B
03/07/24 March 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch